Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00126516
Status:
COMPLETED
Last Update Posted:
2013-10-30
First Post:
2005-08-03
Brief Title:
Angiotensin II Receptor Blockers ARB and ACE Inhibitors ACEI on Silent Brain Infarction and Cognitive Decline
Sponsor:
Nara Medical University
Organization:
Nara Medical University
Study Overview
Official Title:
Effects of Angiotensin II Receptor Blockers ARB and Angiotensin Converting Enzyme Inhibitors ACEI on Progression of Silent Brain Infarction and Cognitive Decline in Japanese Patients With Essential Hypertension in the Elderly
Status:
COMPLETED
Status Verified Date:
2013-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to elucidate whether or not angiotensin II receptor blockers ARB are more beneficial or equal to angiotensin converting enzyme inhibitors ACEI on development or progression of silent brain infarction and cognitive decline in Japanese patients with essential hypertension in the elderly
Detailed Description:
Hypertension plays a major role in the development of cardiovascular diseases Treating hypertension has been associated with reduction in the risk of stroke and myocardial infarction Angiotensin converting enzyme inhibitor ACEI ramipril showed a 32 in relative risk of reduction in the Heart Outcomes Prevention Evaluation HOPE trial Angiotensin II receptor blocker ARB losartan also showed a 25 in relative risk of reduction in the Losartan Intervention For Endpoint reduction in hypertension study LIFE
Elderly people especially hypertensive patients with silent brain infarction have an increased risk of stroke and cognitive decline However no reports are seen on comparison of the effects of ARBs and ACEIs on progression of silent brain infarction and cognitive decline in patients with essential hypertension in the elderly
The researchers therefore longitudinally evaluate silent brain infarction using magnetic resonance imaging and cognitive decline by Mini-Mental State Examination twice at an interval of 2 years in patients with essential hypertension in the elderly who are received antihypertensive therapy by ARB or ACEI
Elderly people especially hypertensive patients with silent brain infarction have an increased risk of stroke and cognitive decline However no reports are seen on comparison of the effects of ARBs and ACEIs on progression of silent brain infarction and cognitive decline in patients with essential hypertension in the elderly
The researchers therefore longitudinally evaluate silent brain infarction using magnetic resonance imaging and cognitive decline by Mini-Mental State Examination twice at an interval of 2 years in patients with essential hypertension in the elderly who are received antihypertensive therapy by ARB or ACEI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None